HEMK2 and posterior cortical atrophy: Our data suggest that targeting of mitochondrial KMT9, possibly in combination with drugs targeting metabolic regulators in other cell compartments and/or inhibitors of nuclear KMT9 function, can be exploited as a potential therapeutic approach for the treatment of PCa.